4-HO-MPMI

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine
4-HO-N-Me-TMT.png
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H17N2O
Molar mass229.297 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)-tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.[1]

The binding affinity for 5-HT2A receptor is 13 ± 2 nM (Ki [125I]DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six and eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety.[2][unreliable source?]

See also[edit]

References[edit]

  1. ^ Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE (1999). "Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain". Journal of Medicinal Chemistry. 42 (20): 4257–4263. CiteSeerX 10.1.1.690.4941. doi:10.1021/jm990325u. PMID 10514296.
  2. ^ http://www.hipforums.com/newforums/showthread.php?t=315326